Evidence map›Paper›PMID 38225412›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2024

Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders.

Aditi Giri, Sidharth Mehan, Zuber Khan, Ghanshyam Das Gupta, Acharan S Narula, Reni Kalfin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Aditi GiriDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, India.
Sidharth MehanDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, India. sidh.mehan@gmail.com.ORCID http://orcid.org/0000-0003-0034-835X
Zuber KhanDivision of Neuroscience, Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, India.
Ghanshyam Das GuptaDepartment of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.
Acharan S NarulaNarula Research, LLC, 107 Boulder Bluff, Chapel Hill, NC, 27516, USA.
Reni KalfinInstitute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev St., Block 23, Sofia, 1113, Bulgaria.
Indo Soviet Friendship College of Pharmacy · INSouth-West University "Neofit Rilski" · BG

Funding

Science and Engineering Research Board Core Research Grant; Grant Number: CRG/2021/001009)
6 · The paper itself

Abstract

Neurodegenerative and neuropsychiatric disorders are two broad categories of neurological disorders characterized by progressive impairments in movement and cognitive functions within the central and peripheral nervous systems, and have emerged as a significant cause of mortality. Oxidative stress, neuroinflammation, and neurotransmitter imbalances are recognized as prominent pathogenic factors contributing to cognitive deficits and neurobehavioral anomalies. Consequently, preventing neurodegenerative and neuropsychiatric diseases has surfaced as a pivotal challenge in contemporary public health. This review explores the investigation of neurodegenerative and neuropsychiatric disorders using both synthetic and natural bioactive compounds. A central focus lies on melatonin, a neuroregulatory hormone secreted by the pineal gland in response to light-dark cycles. Melatonin, an amphiphilic molecule, assumes multifaceted roles, including scavenging free radicals, modulating energy metabolism, and synchronizing circadian rhythms. Noteworthy for its robust antioxidant and antiapoptotic properties, melatonin exhibits diverse neuroprotective effects. The inherent attributes of melatonin position it as a potential key player in the pathophysiology of neurological disorders. Preclinical and clinical studies have demonstrated melatonin's efficacy in alleviating neuropathological symptoms across neurodegenerative and neuropsychiatric conditions (depression, schizophrenia, bipolar disorder, and autism spectrum disorder). The documented neuroprotective prowess of melatonin introduces novel therapeutic avenues for addressing neurodegenerative and psychiatric disorders. This comprehensive review encompasses many of melatonin's applications in treating diverse brain disorders. Despite the strides made, realizing melatonin's full neuroprotective potential necessitates further rigorous clinical investigations. By unravelling the extended neuroprotective benefits of melatonin, future studies promise to deepen our understanding and augment the therapeutic implications against neurological deficits.

Indexed as

MelatoninMental DisordersNeurodegenerative DiseasesNeuroprotective AgentsAnimalsAntioxidantsBrainHumansAntioxidantsMelatoninNeuroprotective AgentsAnti-inflammatoryAntioxidantMelatoninNeurodegenerative diseasesNeuropsychiatric diseases

Identifiers

PMID38225412
OpenAlexW4390893762

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.